Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk, early breast cancer - Authors' reply
- PMID: 36858725
- DOI: 10.1016/S1470-2045(23)00065-7
Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk, early breast cancer - Authors' reply
Conflict of interest statement
SRDJ declares research funding from Pfizer, Puma, Biotechnology, Eli Lilly, AstraZeneca, Novartis, Roche–Genetech; consulting fees from Eli Lilly, AstraZeneca, Puma Biotechnology, Pfizer, Novartis, Sanofi, Genzyme; and speakers’ bureau fees from Pfizer, Eisai, AstraZeneca, Roche–Genetech. VA owns stock and is an employee of Eli Lilly.
Comment on
-
Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial.Lancet Oncol. 2023 Jan;24(1):77-90. doi: 10.1016/S1470-2045(22)00694-5. Epub 2022 Dec 6. Lancet Oncol. 2023. PMID: 36493792 Free PMC article. Clinical Trial.
-
Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk, early breast cancer.Lancet Oncol. 2023 Mar;24(3):e103. doi: 10.1016/S1470-2045(23)00014-1. Lancet Oncol. 2023. PMID: 36858724 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous